Literature DB >> 20559203

U S. Medical Eligibility Criteria for Contraceptive Use, 2010.

.   

Abstract

CDC created U.S. Medical Eligibility Criteria for Contraceptive Use, 2010, from guidance developed by the World Health Organization (WHO) and finalized the recommendations after consultation with a group of health professionals who met in Atlanta, Georgia, during February 2009. This guidance comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics or medical conditions. The majority of the U.S. guidance does not differ from the WHO guidance and covers >60 characteristics or medical conditions. However, some WHO recommendations were modified for use in the United States, including recommendations about contraceptive use for women with venous thromboembolism, valvular heart disease, ovarian cancer, and uterine fibroids and for postpartum and breastfeeding women. Recommendations were added to the U.S. guidance for women with rheumatoid arthritis, history of bariatric surgery, peripartum cardiomyopathy, endometrial hyperplasia, inflammatory bowel disease, and solid organ transplantation. The recommendations in this document are intended to assist health-care providers when they counsel women, men, and couples about contraceptive method choice. Although these recommendations are meant to serve as a source of clinical guidance, health-care providers should always consider the individual clinical circumstances of each person seeking family planning services.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20559203

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  97 in total

1.  The impact of out-of-pocket expense on IUD utilization among women with private insurance.

Authors:  Aileen M Gariepy; Erica J Simon; Divya A Patel; Mitchell D Creinin; Eleanor B Schwarz
Journal:  Contraception       Date:  2011-08-17       Impact factor: 3.375

2.  Types of combined oral contraceptives used by US women.

Authors:  Kelli Stidham Hall; James Trussell
Journal:  Contraception       Date:  2012-07-06       Impact factor: 3.375

3.  Positive Testing for Neisseria gonorrhoeae and Chlamydia trachomatis and the Risk of Pelvic Inflammatory Disease in IUD Users.

Authors:  Natalia E Birgisson; Qiuhong Zhao; Gina M Secura; Tessa Madden; Jeffrey F Peipert
Journal:  J Womens Health (Larchmt)       Date:  2015-04-02       Impact factor: 2.681

4.  Healthcare Provider Attitudes Regarding Contraception for Women with Obesity.

Authors:  Tara C Jatlaoui; Lauren B Zapata; Kathryn M Curtis; Suzanne G Folger; Polly A Marchbanks; Michele G Mandel; Denise J Jamieson
Journal:  J Womens Health (Larchmt)       Date:  2017-01-31       Impact factor: 2.681

5.  Evidence-based selection of candidates for the levonorgestrel intrauterine device (IUD).

Authors:  Lisa S Callegari; Blair G Darney; Emily M Godfrey; Olivia Sementi; Rebecca Dunsmoor-Su; Sarah W Prager
Journal:  J Am Board Fam Med       Date:  2014 Jan-Feb       Impact factor: 2.657

6.  Improving the Implementation of Evidence-Based Clinical Practices in Adolescent Reproductive Health Care Services.

Authors:  Lisa M Romero; Dawn Middleton; Trisha Mueller; Lia Avellino; Rachel Hallum-Montes
Journal:  J Adolesc Health       Date:  2015-09-15       Impact factor: 5.012

7.  Contraceptive use in female recipients of a solid-organ transplant.

Authors:  Sally Rafie; Sophia Lai; Juanita E Garcia; Sheila K Mody
Journal:  Prog Transplant       Date:  2014-12       Impact factor: 1.187

Review 8.  Contraception for HIV-Infected Adolescents.

Authors:  Athena P Kourtis; Ayesha Mirza
Journal:  Pediatrics       Date:  2016-09       Impact factor: 7.124

9.  Impact of training level on postplacental levonorgestrel 52 mg intrauterine device expulsion.

Authors:  Madeline Cole; Stephanie Thomas; Brian M Mercer; Kavita Shah Arora
Journal:  Contraception       Date:  2018-11-16       Impact factor: 3.375

10.  Contraceptive counseling and postpartum contraceptive use.

Authors:  Lauren B Zapata; Sarah Murtaza; Maura K Whiteman; Denise J Jamieson; Cheryl L Robbins; Polly A Marchbanks; Denise V D'Angelo; Kathryn M Curtis
Journal:  Am J Obstet Gynecol       Date:  2014-08-02       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.